COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,254 Articles (22,733 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 2602: Articles 26011-26020  | Next

Risk of death by age and gender from CoVID-19 in Peru, March-May, 2020
Munayco, C., Chowell, G., Tariq, A., Undurraga, E. A., Mizumoto, K.
10.1101/2020.06.14.20123315 — Posted: 2020-06-16
Development and validation of a knowledge-driven risk calculator for critical illness in COVID-19 patients
Cahan, A., Gottesman, T., Tzuchman Katz, M., Masad, R., Azulay, G., Dicker, D., Zeidman, A., Berkov, E., Sahaf Levin, G., Tadmor, B., Lev, S.
10.1101/2020.06.14.20103754 — Posted: 2020-06-16
BRAIN MR SPECTROSCOPIC FINDINGS IN THREE CONSECUTIVE COVID-19 PATIENTS: PRELIMINARY OBSERVATIONS
Rapalino, O., Weerasekera, A., Moum, S. J., Eikermann-Haerter, K., Edlow, B. L., Fischer, D., Mukerji, S., Schaefer,, P., Gonzalez, R. G., Lev, M., Ratai, E.-M.
10.1101/2020.06.10.20122465 — Posted: 2020-06-16 Discussion: Onsite
The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types
Daniloski, Z., Guo, X., Sanjana, N. E.
10.1101/2020.06.14.151357 — Posted: 2020-06-15 Discussion: Onsite
Interfacial Water Molecules Make RBD of SPIKE Protein and Human ACE2 to Stick Together
Malik, A., Prahlad, D., Kulkarni, N., Kayal, A.
10.1101/2020.06.15.152892 — Posted: 2020-06-15
Pulmonary toxicity and inflammatory response of e-cigarettes containing medium-chain triglyceride oil and vitamin E acetate: Implications in the pathogenesis of EVALI but independent of SARS-COV-2 COVID-19 related proteins
Muthumalage, T., Lucas, J., Wang, Q., Lamb, T., McGraw, M., Rahman, I.
10.1101/2020.06.14.151381 — Posted: 2020-06-15 Discussion: Onsite
Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry
Ozono, S., Zhang, Y., Ode, H., Seng, T. T., Imai, K., Miyoshi, K., Kishigami, S., Ueno, T., Iwatani, Y., Suzuki, T., Tokunaga, K.
10.1101/2020.06.15.151779 — Posted: 2020-06-15
Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera
Pape, C., Remme, R., Wolny, A., Olberg, S., Wolf, S., Cerrone, L., Cortese, M., Klaus, S., Lucic, B., Ullrich, S., Anders-Össwein, M., Wolf, S., Berati, C., Neufeld, C., Ganter, M., Schnitzler, P., Merle, U., Lusic, M., Boulant, S., Stanifer, M., Bartenschlager, R., Hamprecht, F. A., Kreshuk, A., Tischer, C., Kräusslich, H.-G., Müller, B., Laketa, V.
10.1101/2020.06.15.152587 — Posted: 2020-06-15 Discussion: Onsite
Genome-wide mapping of therapeutically-relevant SARS-CoV-2 RNA structures
Manfredonia, I., Nithin, C., Ponce-Salvatierra, A., Ghosh, P., Wirecki, T. K., Marinus, T., Ogando, N. S., Snijder, E. J., van Hemert, M. J., Bujnicki, J. M., Incarnato, D.
10.1101/2020.06.15.151647 — Posted: 2020-06-15
The SARSCoV2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier
Buzhdygan, T. P., DeOre, B. J., Baldwin-Leclair, A., McGary, H., Razmpour, R., Galie, P. A., Potula, R., Andrews, A. M., Ramirez, S. H.
10.1101/2020.06.15.150912 — Posted: 2020-06-15 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).